19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2525



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace


powered by centersite dot net
Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Coping Support Assists Parents of Hospitalized ChildrenYoung Breakfast Skippers Lack Vital NutrientsA Violent Environment Can Wreck Kids' GradesSleep Duration Inversely Linked to Risk Markers of T2DM in KidsDo Pets Really Boost Kids' Health?Rotavirus Vaccine Cuts U.S. Peds Gastroenteritis HospitalizationsRotavirus Vaccine Cut Kids' Hospitalization, Medical CostsBy Age 12, Poor May Show Signs of Heart Risks AheadHealth Tip: Childhood Obesity Can Trigger Adult ProblemsDecline in Kids' Ear Infections Linked to Pneumococcal VaccinePicky Eater? It Might Just Be Your Child's PersonalityPrenatal Exposure to Certain Flame Retardants Linked to Lower IQsHealth Tip: Protect Your Kids From LeadKnow the Signs of ConcussionSurgeons Warn of Trampolines' Down SideVision Problems Can Harm Kids' Development, GradesTime to Catch Up on Reading, Writing … and Routine ShotsU.S. Kids Overdosing on Dietary SupplementsJust a Few Vaccine Refusers Could Endanger ManyDoes Your Child Really Have a Food Allergy?Donor-Sperm Kids No Different From Their Peers: StudyHigh-Dose Vitamin D May Not Curb Kids' ColdsHealth Tip: Check the Water Before SwimmingDespite Warnings, Kids Are Still Dying in Hot CarsLink for Maternal Antidepressant, Kids' Brain Health QuestionedToo Few Children Get EpiPen When Needed: StudyHealth Tip: Take Care of Kids Exercising in Summer HeatHow to Prevent Future Couch PotatoesSugar Intake During Pregnancy Tied to Allergy in OffspringThe Neighborhood Sandbox: A Breeding Ground for GermsRisks Linked to Soft Contacts No Higher for Children Than AdultsSmoking On the Rise in Movies Aimed at Young: StudyBullying Takes Financial Toll on U.S. School DistrictsSwimming Lessons: For Starters, Watch Out for Germs in the WaterHow to Keep Your Kids Out of the ER This SummerIs Your Child's 'Penicillin Allergy' Real?Health Tip: When Adults Offer Kids FoodHealth Tip: Practice Drowning Prevention at HomeCommunity Intervention May Aid Fight Against Childhood ObesityGetting Kids in the Habit of Healthy EatingHealth Tip: Rewarding Kids Without FoodDo Older Dads Produce Brainy Boys?USPSTF Concludes Screening for Obesity Beneficial for ChildrenFirearms Kill or Wound 7,000 U.S. Children AnnuallyGuns Kill or Wound 7,000 U.S. Kids a Year: ReportTime for Some Summer Sun Safety TipsHealth Tip: Applying Sunscreen on ChildrenMany Preemies Don't Struggle in SchoolHealth Tip: When Your Child Won't Eat LunchResearchers Target Zolmitriptan Dosing for Pediatric Migraine
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting

Direct-Acting Antivirals Approved for Children 12+ With HCV


HealthDay News
Updated: Apr 10th 2017

new article illustration

MONDAY, April 10, 2017 (HealthDay News) -- The U.S. Food and Drug Administration has approved two drugs to treat hepatitis C virus (HCV) infection in children aged 12 and older.

Sovaldi (sofosbuvir) and Harvoni (ledipasvir, sofosbuvir) are the first direct-acting antiviral treatments approved for children and adolescents with HCV, the agency said in a news release Friday.

The two approvals provide pediatric treatment options for six major genotypes of HCV: Harvoni is indicated for the treatment of pediatric patients ≥12 years or weighing ≥35 kg with HCV genotype 1, 4, 5, or 6 infection without cirrhosis or with mild cirrhosis. Sovaldi in combination with ribavirin is indicated for the treatment of pediatric patients ≥12 years or weighing ≥35 kg with HCV genotype 2 or 3 infection without cirrhosis or with mild cirrhosis.

In clinical studies, the most common side effects of both drugs were fatigue and headache. Health care professionals should screen all patients for evidence of current or prior hepatitis B virus infection before starting treatment with Harvoni or Sovaldi, the agency advised.

"These approvals will help change the landscape for HCV treatment by addressing an unmet need in children and adolescents," Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, said in a statement.

Harvoni and Sovaldi are marketed by Gilead Sciences, in Foster City, Calif.

More Information